[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Di Lorenzo C., Coppola G., Sirianni G., Di Lorenzo G., Bracaglia M., Di Lenola D., Siracusano A., Rossi P., Pierelli F
Published 2025 Sep 19
It will not shut off the signals to just not eat which is a benefit for those who balanced nutrition and help with the urges thru the day to snack
Always consult a qualified healthcare provider before starting or changing any treatment.
As with other incretin-based therapies, the most commonly reported adverse effects in the retatrutide phase 2 trial were gastrointestinal in nature
Data from the European LEOSS registry as well as other data show an additive effect of obesity, diabetes, and hypertension on the risk of mortality, which is higher in young and middle-aged patients (1855 years)